Seattle Biotech Duped Investors On Drug Progress, Suit Says

Seattle's Sana Biotechnology Inc. is the target of a proposed class action filed on Monday by a shareholder who alleges the company misled investors about its ability to develop genetic therapy...

Already a subscriber? Click here to view full article